CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis Research

Executive Summary: CA-074 is a potent and selective inhibitor of cathepsin B (Ki = 2–5 nM) that does not significantly inhibit cathepsins H or L at comparable concentrations (<40–200 μM Ki) [APExBIO, 2024]. Chemical inhibition of cathepsin B using CA-074 blocks lysosome-mediated cell death in necroptosis models (Liu et al., 2023). In vivo, CA-074 reduces bone metastasis without affecting primary tumor size in mouse breast cancer models [APExBIO, 2024]. CA-074 modulates immune responses by shifting Th-2 to Th-1 activity and decreasing IgE/IgG1 levels [CA074.com, 2024]. The compound demonstrates low cytotoxicity (≤10 mM, cell culture) and high solubility in DMSO, ethanol, and water.

Biological Rationale

Cathepsin B (CTSB) is a lysosomal cysteine protease involved in protein catabolism, extracellular matrix remodeling, and regulated cell death. Dysregulated cathepsin B activity is implicated in cancer metastasis, neuroinflammation, and necroptosis (Liu et al., 2023). In necroptosis, MLKL polymerization induces lysosomal membrane permeabilization (LMP), releasing cathepsin B into the cytosol and triggering cell death. Cathepsin B also regulates immune signaling and influences helper T cell differentiation. Selective inhibition of CTSB enables researchers to dissect its role in these pathways without off-target effects on related cathepsins.

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a peptidyl epoxide that covalently binds to the active site cysteine of cathepsin B, blocking substrate hydrolysis. It displays a high affinity for CTSB (Ki = 2–5 nM) and negligible activity toward cathepsins H or L (Ki = 40–200 μM) [APExBIO, 2024]. In necroptosis, CA-074 prevents cathepsin B–mediated cleavage of essential cellular proteins, reducing cell death after lysosomal membrane rupture (Liu et al., 2023). In cancer models, CA-074 blocks proteolytic cascades required for tumor cell invasion and metastatic colonization. In immune cells, inhibition of CTSB by CA-074 alters cytokine production and helper T cell polarization from Th-2 to Th-1, reducing humoral immune responses [CA074.com, 2024].

Evidence & Benchmarks

• CA-074 inhibits cathepsin B with a Ki of 2–5 nM and demonstrates >8,000-fold selectivity over cathepsins H and L (Ki = 40–200 μM) (APExBIO, 2024).
• Chemical inhibition of cathepsin B with CA-074 protects cells against necroptosis following MLKL-induced lysosomal membrane permeabilization (Liu et al., 2023).
• In a 4T1.2 breast cancer mouse model, intraperitoneal administration of CA-074 (50 mg/kg) reduces bone metastasis without affecting primary tumor volume (APExBIO, 2024).
• CA-074 inhibits neurotoxicity in Abeta42-activated microglial models, decreasing neuronal cell death (CA074.com, 2024).
• CTSB inhibition by CA-074 alters helper T cell polarization from Th-2 to Th-1, reducing IgE and IgG1 production (CA074.com, 2024).
• Shows negligible cytotoxicity in cell culture at ≤10 mM (ApexApoptosis, 2024).
• Soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL, ultrasonic assistance) (APExBIO, 2024).

This article extends the mechanistic focus of CA-074: Advancing Cathepsin B Inhibition for Mechanistic ... by providing additional peer-reviewed necroptosis data on MLKL-LMP-CTSB axis, and clarifies selectivity benchmarks highlighted in CA-074: Selective Cathepsin B Inhibitor for Cancer Metast... with comparative in vivo efficacy.

Applications, Limits & Misconceptions

CA-074 is a tool compound for dissecting cathepsin B function in cancer metastasis, necroptosis, and neurotoxicity. It is used in cell-based assays, animal models, and immune response studies. The compound's high selectivity supports studies aiming to isolate CTSB-specific effects. However, as with all chemical inhibitors, careful control experiments and orthogonal validation (e.g., genetic knockdown) are recommended.

Common Pitfalls or Misconceptions

• CA-074 does not significantly inhibit other cathepsins (e.g., D, H, L) at concentrations effective against CTSB.
• Solubility in water is limited; ultrasonic assistance is required for >5.91 mg/mL dissolution.
• CA-074 is not suitable for long-term solution storage; fresh preparations are advised for experimental reproducibility.
• In vivo use is best supported in rodent models; pharmacokinetics in larger animals or humans are not fully characterized.
• Not all cell death pathways are CTSB-dependent; CA-074 is ineffective in apoptosis models where CTSB is not engaged.

Workflow Integration & Parameters

CA-074, Cathepsin B inhibitor (A1926; product page), is supplied as a solid small molecule (MW = 383.44 g/mol). For in vitro use, dissolve in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), or water (>5.91 mg/mL with ultrasonic assistance). Stock solutions should be stored at –20°C and used within days. In cell culture, effective concentrations range from 0.1–10 μM. In vivo, a 50 mg/kg dose (intraperitoneal, mouse) reduced bone metastasis without affecting primary tumor growth. Cytotoxicity is negligible at ≤10 mM in standard cell lines. For immune assays, CA-074 enables modulation of Th-2/Th-1 balance and immunoglobulin production. Refer to this workflow article for protocol adaptations; this article details new benchmarks for necroptosis and neurotoxicity not previously covered.

Conclusion & Outlook

CA-074 remains a gold-standard selective cathepsin B inhibitor for mechanistic research in cancer metastasis, regulated cell death, and immune modulation. Its nanomolar potency, robust selectivity, and low cytotoxicity profile enable precise dissection of CTSB-dependent pathways. As new findings clarify the central role of lysosomal protease release in necroptosis and metastasis, CA-074’s applications continue to expand. For detailed protocols and sourcing, researchers should consult the APExBIO A1926 product page.